MedTrace Logo

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

NCT05886790 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2023-06-02

No results posted yet for this study

Summary

This is an open-label, randomized, parallel-controlled clinical trial conducted in people aged 18 years and older to evaluate the immunogenicity and safety of two SARS-CoV-2 bivalent vaccines constructed by adenovirus type 5-based or mRNA-based technics.

Conditions

Interventions

BIOLOGICAL

Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation

Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively

BIOLOGICAL

Bivalent COVID-19 mRNA Vaccine

Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively

BIOLOGICAL

Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation

Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type

Sponsors & Collaborators

  • Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

    collaborator OTHER

  • Zhongnan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2023-12-31
Completion
2024-05-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886790 on ClinicalTrials.gov